September 2007 Fingertip Formulary Insights™
Key Findings
- Big Three: Vytorin, Lipitor and Crestor are the leaders in tier 1 and 2 availability for commercial plans. Vytorin has 69% tier 1/2 availability (as a percentage of covered lives), while Lipitor has 62% tier 1/tier 2 availability.
- Who gained ground: Crestor made a significant move in the 2nd half of 2006 and early 2007, with its availability on tiers 1 and 2 increasing from 36% from July 2006 to over 50% in 2007.
- Who lost ground: As a result of the availability of generic simvastatin in June 2006, Zocor’s tier 1/2 availability declined from 69% in July 2006 to under 10% by January 2007. In the commercial market, Zocor’s tier 1/2 availability declined more rapidly, compared to the Medicare market. Lipitor lost approximately 10% in absolute terms during the year.
Printable version (PDF 332KB)
Archives
December 2007: Lack of Impact from Two Key Generics in the Anti-depressant Formulary Market
October 2007: Formulary Position Differences between Commercial and Medicare Plans
September 2007: Impact of Patent Loss for Zocor on the Statin Marketplace
- Intro
- Commercial Plans
- Medicare Plans
- Restriction Analysis
- Market Basket
Statins – Commercial Plans – Tier 1 and 2 Availability
